First Light Asset Management LLC Sells 125,261 Shares of Insulet Co. (NASDAQ:PODD)

First Light Asset Management LLC lowered its stake in Insulet Co. (NASDAQ:PODD - Free Report) by 78.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,821 shares of the medical instruments supplier's stock after selling 125,261 shares during the quarter. First Light Asset Management LLC's holdings in Insulet were worth $8,830,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Virtu Financial LLC bought a new position in shares of Insulet during the 3rd quarter worth about $616,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Insulet during the third quarter worth approximately $114,000. Tidal Investments LLC raised its position in shares of Insulet by 5.2% during the third quarter. Tidal Investments LLC now owns 9,365 shares of the medical instruments supplier's stock worth $2,180,000 after purchasing an additional 466 shares during the period. Synovus Financial Corp grew its position in Insulet by 36.1% in the 3rd quarter. Synovus Financial Corp now owns 2,929 shares of the medical instruments supplier's stock valued at $682,000 after purchasing an additional 777 shares during the period. Finally, B. Riley Wealth Advisors Inc. bought a new position in shares of Insulet in the third quarter valued at $202,000.

Insulet Price Performance

PODD traded down $2.04 on Thursday, reaching $250.25. The company had a trading volume of 596,700 shares, compared to its average volume of 716,142. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $289.46. The company has a market cap of $17.57 billion, a price-to-earnings ratio of 43.22, a P/E/G ratio of 3.62 and a beta of 1.30. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The business has a 50 day simple moving average of $258.37 and a 200 day simple moving average of $261.95.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, beating analysts' consensus estimates of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business had revenue of $597.50 million for the quarter, compared to analysts' expectations of $582.02 million. As a group, sell-side analysts anticipate that Insulet Co. will post 3.92 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on PODD. Raymond James reiterated an "outperform" rating and set a $328.00 price target (up previously from $294.00) on shares of Insulet in a report on Friday, February 21st. StockNews.com downgraded shares of Insulet from a "buy" rating to a "hold" rating in a report on Tuesday, March 4th. Stifel Nicolaus upped their price objective on shares of Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a research report on Friday, February 21st. Wells Fargo & Company set a $322.00 target price on shares of Insulet in a research report on Monday. Finally, TD Cowen upped their target price on Insulet from $264.00 to $324.00 and gave the company a "buy" rating in a report on Friday, January 3rd. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, Insulet currently has an average rating of "Moderate Buy" and an average price target of $293.94.

Insider Buying and Selling

In other news, Director Wayne A.I. Frederick sold 1,825 shares of Insulet stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the transaction, the director now owns 3,231 shares in the company, valued at approximately $888,525. The trade was a 36.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.47% of the stock is currently owned by corporate insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.